TNO Triskelion BSL-3 lab tests anti-viral drugs in newly developed H7N9 influenza model Human infections with a new avian influenza A (H7N9) virus were first reported in China in 2013, with the loss of 46 lives. In order to meet the growing needs to test new drugs against H7N9, TNO Triskelion has recently developed an H7N9 mouse model. This H7N9 model is suitable for testing new anti-virals such as vaccines, monoclonal antibodies and small molecules in our BSL-3 lab, in conformity with Good Laboratory Practice. TNO Triskelion has proven to be a successful partner in the development of new anti-viral and anti-bacterial vaccines for many years. Understanding the pressures on time lines, we support companies and institutes during the preclinical and clinical stages of drug development.

1. Infectious Diseases
TNO Triskelion is your independent
and trusted pre-clinical research
partner. We provide sponsor-speci-fic
support for pre-clinical develop-ment
of your vaccine products
against infectious diseases. Our
certified and accredited Bio Safety
Level 2 and 3 facilities allow us to
evaluate your vaccines that require
BSL2 or BSL 3 testing facilities.
TNO Triskelion facilities supports
your market authorisation process
for new vaccines against infection
and deadly pathogens.
Our reports have successfully
supported the market authorisation
for vaccines of our clients around
the globe.
WHAT’S IN IT FOR YOU?
With over 30 years of vaccine safety and
efficacy testing, we are confident that we
will provide you with the research approach
you need.
WE OFFER:
- Biosafety Level 2 & 3 facility
- Expertise & experience in class 2
and class 3 challenge studies
- Tailor-made study designs
- Flexibility
- Proven track record
- Direct contact with our experts
- Available infectious disease
efficacy models:
- Influenza H1, H3 and B
- Hepatitis B
- GLP and non-GLP services
- Regulatory guideline compliance
BSL 2 & 3 CAPABILITIES:
- Challenge studies up to class 3 pathogens:
- Avian influenza (H5N1, H7N7, H7N9)
- SARS, HIV, Hepatitis B
- Bacteria (i.e. tuberculosis, polio)
- Efficacy testing of anti-viral and
anti-bacterial vaccines
- Small molecules and biologics
- Regulatory-compliant virus propagation
and quantitation (TCID50) services
- Mouse-adapted influenza strains available
- Bio-analytical support
PHARMA

2. tnotriskelion.com
Evaluation and
Authorization
BIOANALYTICAL SERVICES
LIGAND BINDING ASSAYS:
- ELISA
- Luminex
- Mesoscale Discovery
- Serum IgM and IgG isotype titres
- small molecule serum/plasma analysis
- Cytokine, chemokine and phospho-protein
analysis in various matrices
LC-MS:
- Serum antibody of small molecule
analysis
- Antibody fragments in serum and tissues
(i.e. nose/lungs)
YOUR BENEFITS:
- Fast turnaround times
- Direct communication with expert
- Tailor-made study designs
- Full regulatory & ethical compliance
- GLP or non-GLP services
- Consultancy on 3R’s (Refinement,
Replacement and Reduction) of animal
testing
- Knowledgeable staff: 15% PhDs
- AAALAC accreditation
- GLP-certified facilities
- ISO17025-certified analytical labs
ECHA
Technical
Guidance
Products and
services
Triskelion
New
PATHOGEN SERVICES
VIRAL PROPAGATION SERVICES:
- Propagation on SPF eggs
- Endotoxin detection
- Mycoplasma detection
- Viral genome sequencing
to successful REACH compliance, which
is crucial for your licence to operate.
Being well prepared can make your
contacts with the authorities more
confident and meaningful, assisting in
a smooth and successful inspection.
TCID50
Using the MDCK cell line the TCID50 is
determined for:
- Viral stocks
- Tissue viral load
OUR SOLUTIONS
an audit may include a review of the
following aspects:
• REACH obligations and the expectations
of inspectors.
• Substance inventory.
• Efficiency of current purchasing
processes (including customs).
• The process for classification and
labelling of substances/products.
• The REACH obligations on the use of
hazardous substances.
• The management of (extended) SDSs.
• The practical implications of REACH in
the company/plant.
• Downstream user / supply chain
communication.
• Internal documentation / archiving.
• Internal communication and training of
personnel regarding rEaCh.
• Current IT-tools to facilitate the above
processes.
IN LIFE EFFICACY MODELS AVAILABLE
FOR INFLUENZA AND HEPATITS B:
- Mice
- Rats
- Ferrets
Other pathogens on request
CHALLENGE STUDY READ-OUTS:
- Body weight
- Clinical score
PATHOLOGY SUPPORT:
TISSUE (IMMUNO)HISTOPATHOLOGY
- H&E staining
- Immunohistochemistry
- Cytospin analysis of tissue infiltrates
- FACS analysis of tissue infitrates
- Broncho-Alveolar Lavage Fluid Analysis
MOLECULAR BIOLOGY:
- Whole genome sequencing
- Real-time qPCR
WHY TNO TRISkeLION
• Strong REACH team: regulatory
scientists highly experienced in
chemical industry, with EU Competent
authorities and contract research.
• Experience with more than 200 REACH
projects for major chemical industry
clients: consortium representation, lead
dossier generation, company dossiers.
• working in the interest of our clients,
anticipating the wishes of authorities.
See our website (www.triskelion.nl) for
more information on tailor-made support
to assist your company for REACH, ClP,
Chemicals Management and Biocides.
R E A C H AU D I T S
REACH9/12-11/Ck/0755
Manufacture
Ensured
Succesful
registration
Chemical Industry & REACH
Defensive
Strategies
Dossier
Completion
Exposure Tools,
Testing &
Analysis
>1000t Annex X
Substances
100-1000t Annex
IX & X Substances
Partners
S trate gie s
REACH And TnO TRiskEliOn:
suCCEssful REgisTRATiOn ‘wiTHin REACH’
The aim of REACH is to describe the safe-use of chemicals
throughout the product chain. All High Production Volume
Chemicals and priority substances must be registered by
2010 or 2013. TNO Triskelion can assist your company in
achieving this with our proven expertise in the fields of risk
assessment, registration and testing. With TNO Triskelion,
your technical dossiers, exposure scenarios and Chemical
Safety Reports are safe in our hands.
The added value of TNO Triskelion’s REACH services is
based on decades of experience with registration and
safety studies for the Chemicals Industry. TNO Triskelion is
actively involved in the rgw ongoing work of developing
technical guidance for REACH and has broad contacts with
ECHA and the EU Member State Competent Authorities.
www.TRISkElIon.nl
TnO TRISkElIOn BV
TnO Triskelion is a contract research
organization active in toxicology research,
analytical chemistry and chemical risk
analyses. The mission of TnO Triskelion is
to guarantee the quality and safety of food
ingredients, chemical substances and
medicines. TnO Triskelion is a subsidiary
of TnO, the netherlands Organisation for
Applied Scientific Research.
VISITIng ADDRESS
utrechtseweg 48
3704 HE Zeist
the netherlands
POSTAl ADDRESS
P.O. Box 844
3700 AV Zeist
the netherlands
for more information, please contact us.
THE nETHERlAnDS
P +31 88 866 16 20
f +31 88 866 69 70
chemistry@tno.triskelion.nl
Japan
P +81 45 478 51 30
f +81 45 473 79 59
“ MAjOR REsulTs:
inCREAsEd
AwAREnEss And
HARMOnisATiOn”
When you look for a trusted independent
research partner who can offer full support
in assessing the safety and efficacy of your
Products, TNO Triskelion offers a complete
portfolio of high quality and innovative
services with over 35 years of experience.
We operate in compliance with the highest
quality standards, including GLP, ISO17025
and AAALAC. TNO Triskelion has a track
record of conducting tailor-made studies
by integrating expert knowledge and
flexibility to meet your schedules.
VISITING ADDRESS
Utrechtseweg 48
3704 HE Zeist
The Netherlands
POSTAL ADDRESS
P.O. Box 844
3700 AV Zeist
The Netherlands
For more information, please contact us.
THE NETHERLANDS
P +31 88 866 16 20
F +31 88 866 69 70
pharma@tno.triskelion.nl
JAPAN
P + 81 36 234 41 95
ariga@tno-pharma.com
USA
P +1 416 837 7500
tmeijers@tnopharma.com
Infectious Diseases